IP Library Granted Patent US 8,329,888
Granted Patent B2
US 8,329,888 · App. 12/294,126 · Granted Dec 11, 2012

Small internally segmented interfering RNA

Assignee: Santaris Pharma A/S
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,329,888
App. No.
12/294,126
Granted
Dec 11, 2012
Kind
B2
Abstract

The present invention is directed to pharmaceutical and therapeutic compositions which comprise RNA complexes comprising an antisense strand and a discontinued passenger strand capable of regulating gene expression. The use of a discontinued passenger strand reduces off target effects of the RNA complexes and also has other advantages.

Claims (10)

1. An RNA complex, capable of mediating RNA interference, comprising a core substantially double-stranded region of between 18-23 base pairs, said core substantially double stranded region consisting of an antisense strand and a discontinuous passenger strand; wherein the discontinuous passenger strand is hybridized to the antisense strand, and; wherein the discontinuity in the passenger strand is a nick or a gap of 1 nucleotide, and; wherein the RNA complex comprises one or more LNA units, and; wherein the discontinuous passenger strand comprises at least a first and a second RNA-molecule, and; wherein the first RNA molecule of the discontinuous passenger strand is 8-13 nucleobases in length and the second molecule of the discontinuous passenger strand is 8-14 nucleobases in length, and; wherein first and second RNA molecules of the passenger strand each comprises at least one LNA unit.

2. The RNA complex according to claim 1 , wherein first RNA molecule of the passenger strand comprises at least two LNA units.

3. The RNA complex according to claim 1 , wherein second RNA molecule of the passenger strand comprises at least two LNA units.

4. The RNA complex according to claim 1 , wherein the first and the second RNA molecule of the passenger strand each comprise at least two LNA units.

5. The RNA complex according to claim 1 , wherein an LNA unit is located within the three 3′ terminal nucleotides of the first and second RNA molecules of the passenger strand.

6. The RNA complex according to claim 1 , wherein the antisense strand comprises at least one LNA unit within the duplex region formed with the discontinuous passenger strand.

7. The RNA complex according to claim 1 , wherein at least one the LNA units present in the discontinuous passenger strand forms a base pair with a complementary LNA unit present in the antisense strand.

8. The RNA complex according to claim 1 , wherein the antisense strand comprises a 3′-overhang of 1, 2 or 3 nucleotides.

9. The RNA complex according to claim 1 , wherein the passenger strand comprises a 3′-overhang of 1, 2 or 3 nucleotides.

10. The RNA complex according to claim 1 , wherein both the antisense strand and the passenger strand comprises a 3′-overhang of 1, 2 or 3 nucleotides.

Assignments (3)
CHANGE OF NAME Recorded May 22, 2015
From: SANTARIS PHARMA A/S
To: ROCHE INNOVATION CENTER COPENHAGEN A/S
Reel/Frame 035759/0949 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2009
From: SYDDANSK UNIVERSITET; AARHUS UNIVERSITET
To: SANTARIS PHARMA A/S
Reel/Frame 022262/0822 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2009
From: WENGEL, JESPER; KJEMS, JORGEN
To: SYDDANSK UNIVERSITET; ARHUS UNIVERSITET
Reel/Frame 022263/0220 →
Priority Claims (2)
DK 200600433 · Mar 23, 2006 · national
DK 200601254 · Sep 28, 2006 · national
Continuity (1)
Related Publication 20090182136A1 · Jul 16, 2009